FDA slows down on drug reviews, approvals amid Trump admin chaos
FDA drug approvals slowed, review delays and rejections increased, manufacturing inspection issues rose, and a government shutdown prevents accepting new drug submissions.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Oct 2025)
Eli Lilly's stock surged over 635% since late 2020, driven by new drugs, regulatory wins, pipeline and manufacturing investments, despite a recent revenue shortfall and high valuation.